Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819614 | 0.79 | ADRA2C (0.33) | TNKSPARP1TNKS2TP53ADRA2C | |
| SCHEMBL16707769 | 0.73 | TP53 (0.42) | TNKSPARP1TNKS2TP53ADRA2C | |
| SCHEMBL22504862 | 0.71 | TP53 (0.31) | TP53 | |
| SCHEMBL8661929 | 0.70 | TSHR (0.30) | — | |
| SCHEMBL14315861 | 0.68 | BRD4 (0.38) | ADRA2CMEN1ALDH1A1KMT2AGAA | |
| SCHEMBL29941513 | 0.67 | CNR2 (0.46) | TP53ADRA2CMEN1ALDH1A1KMT2A | |
| SCHEMBL8276420 | 0.67 | CNR2 (0.46) | TP53ADRA2CMEN1ALDH1A1KMT2A | |
| SCHEMBL20353777 | 0.66 | MAOA (0.46) | ADRA2CMEN1ALDH1A1KMT2AGAA | |
| SCHEMBL159025 | 0.64 | ALDH1A1 (0.58) | MEN1ALDH1A1KMT2AGAA | |
| SCHEMBL29699544 | 0.64 | ALDH1A1 (0.58) | MEN1ALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023124537-A1 | CONJUGATE AND ANTIBODY-DRUG CONJUGATE PREPARED USING SAME | 辽宁键凯科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20210300972-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300972-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | FCGR3B, FCGR2A, QPCTL | TNKS 4417/4885PARP1 1930/4885TNKS2 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.